{"id":"NCT01559012","sponsor":"A.O.U. Citt√† della Salute e della Scienza","briefTitle":"Transdermal Clonidine in the Treatment of Severe Hyperemesis Gravidarum","officialTitle":"The CLONEMESI Study: a Randomized Placebo-controlled Study With Transdermal Clonidine in the Treatment of Severe Hyperemesis Gravidarum.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-02","primaryCompletion":"2012-12","completion":"2012-12","firstPosted":"2012-03-20","resultsPosted":"2014-04-30","lastUpdate":"2014-04-30"},"enrollment":13,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hyperemesis Gravidarum"],"interventions":[{"type":"DRUG","name":"Clonidine","otherNames":["Catapresan TTS 2 transdermal patch"]}],"arms":[{"label":"clonidine first - placebo second","type":"OTHER"},{"label":"placebo first - clonidine second","type":"OTHER"}],"summary":"CLONEMESI is an academic, independent, randomized placebo-controlled trial to assess the effect of transdermal (TD) clonidine in improving the symptoms of severe Hyperemesis Gravidarum(HG) affecting women in their 6th-12th week of pregnancy. The study has a crossover design.","primaryOutcome":{"measure":"PUQE Score for Assessment of Severity in Hyperemesis Gravidarum","timeFrame":"Mean values of first period of five days are compared with mean values of second period of five days. Change is reported as baseline value - value at day 5 or at day 10.","effectByArm":[{"arm":"Clonidine","deltaMin":6.3,"sd":null},{"arm":"Placebo","deltaMin":8.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.001"},{"comp":"OG000 vs OG001","p":"<0.02"}]},"eligibility":{"minAge":null,"sex":"FEMALE","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":1},"locations":{"siteCount":1,"countries":["Italy"]},"refs":{"pmids":["24684734"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":6},"commonTop":["Itching"]}}